Navigation Links
Rutgers receives $2.3 million federal grant to research use, safety of antipsychotics
Date:10/21/2008

NEW BRUNSWICK, N.J. Rutgers, The State University of New Jersey, has received a $2.3 million grant from the federal Agency for Healthcare Research and Quality (AHRQ) and the Food and Drug Administration (FDA) to lead a major study of use, safety and effectiveness of antipsychotic medications.

These medications have come to be widely used in a clinically diverse population, including many children and adolescents with such behavioral disorders as aggression and elderly persons with symptoms of dementia, as well as adults with schizophrenia and other serious mental illnesses. Use of antipsychotic medications has increased and broadened with the advent of newer, "atypical" antipsychotic drugs perceived as safer than older drugs, according to principal investigator Professor Stephen Crystal of Rutgers' Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes.

However, as the AHRQ and FDA noted in their request for applications, evidence remains incomplete on safety and effectiveness in various subpopulations of patients treated with these medications, Crystal said. Areas of particular concern include use in youth and in the elderly. Crystal, whose center is a unit of the Institute for Health, Health Care Policy and Aging Research (IHHCPAR), said that Harvard Medical School/Brigham and Women's Hospital, Vanderbilt University and Columbia University are partners in the Rutgers-led consortium.

Investigative teams will conduct three substudies using large, linked health care datasets. The first will focus on outcomes in the institutionalized elderly to examine medical outcomes, such as mortality, stroke, myocardial infarction, as well as cognitive function and behavioral symptoms of dementia. The Rutgers team will expand a research dataset developed through the AHRQ-funded Center for Education and Research on Mental Health Therapeutics, to support analyses by Harvard and Rutgers investigators on medication outcomes on several million nursing home residents across the nation.

A second substudy, examining medication outcomes for children and adolescents, will combine analyses of Medicaid claims, medical charts and electronic medical record data in Tennessee (led by Vanderbilt investigators) with Rutgers-based analyses of national Medicaid data. The third substudy will examine several populationwide safety issues across the age spectrum, including risks of pituitary tumors, diabetes and outcomes for elderly with dementia who live in the community.

"The initiative by AHRQ and the FDA to fund this study represents a significant step forward in helping to provide better information on the outcomes of therapies that are used by large numbers of elderly persons, youth and other patients," Crystal said.

"We are very pleased that the important program of work at the institute on the use and outcomes of mental health medications has been recognized by this award," added Professor David Mechanic, director of the IHHCPAR.


'/>"/>

Contact: Steven Manas
smanas@ur.rutgers.edu
732-932-7084
Rutgers University
Source:Eurekalert

Related medicine news :

1. Rutgers research identifies brain cells related to fear
2. NYU, Rutgers study shows how using mental strategies can alter the brains reward circuitry
3. Rutgers scientist receives prestigious Young Investigator Award
4. Rutgers researchers show how the brain can protect against cancer
5. The Healthcare Foundation of NJ awards grant to Rutgers College of Nursings Rachel Jones
6. 2 Rutgers College of Nursing Ph.D students to receive FNSNA Fellowships
7. Rutgers College of Nursings Linda Flynn to receive N.J. Governors Nursing Merit Award
8. Rutgers research partner Stemcyte, Inc., expands to New Jersey
9. The Zonta Club of Essex County honors Rutgers College of Nursings Rachel Jones
10. Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing
11. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: